查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年偏头痛治疗的全球市场
市场调查报告书
商品编码
1279679

2023-2030 年偏头痛治疗的全球市场

Global Migraine Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球偏头痛药物市场预计将在 2022 年达到 40.358 亿美元，到 2030 年达到 97.911 亿美元，增长势头良好。 由于全球偏头痛的增加，人们对偏头痛及其治疗的认识不断提高，预计在预测期内（2023-2030 年），偏头痛治疗市场的复合年增长率将达到 12.1%。 此外，不断增长的需求和对安全有效治疗的研究和开发的增加预计将推动市场增长。

市场动态

在预测期内，治疗的进步有望推动偏头痛治疗市场的增长

预计在预测期内，新药和新药物输送系统（针头注射、滴鼻剂）等治疗方法的进步将推动全球偏头痛治疗市场的增长。 例如，与在 30 分钟内表现良好的现有治疗相比，这些药物中的一些可以在偏头痛发作后 2 至 4 小时内得到治疗。

临床研究资金的增加为偏头痛药物市场带来了增长机会

增加对主要市场参与者的资助确保了全球偏头痛治疗市场在未来几年的增长机会。 例如，2022 年 8 月，专注于偏头痛护理的以色列数字疗法设计师 Theranica 筹集了约 4500 万美元的 C 系列资金。

COVID-19 影响分析

对 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之后的情景、价格动态（与 COVID 之前的情景相比，大流行期间和之后的价格变动）、供需范围（由于供应和需求的变化贸易限制、封锁和后续问题）；努力）也将被解释。

俄乌衝突分析

乌克兰和俄罗斯都是国际临床试验活动的广泛基地。 对乌克兰的袭击可能会破坏全球药物开发成果，包括偏头痛药物，因为这两个国家的潜在招募地点都失败了。 军事衝突造成的中断对医疗保健产生重大影响，包括偏头痛药物。

全球经济衰退影响分析

医疗保健行业也不能完全免受衰退的影响。 但由于其固有的性质，它比其他行业处理得更好。 然而，随着通胀继续上升，经济衰退危机威胁着市场。 持续衰退导致的紧张局势加剧可能会在未来几年对市场产生重大影响。

人工智能影响分析

2023 年 5 月，虚拟临床试验平台提供商 Healint 与日本埼玉医科大学医院合作，试验如何利用 AI 检测偏头痛。 该研究将由 Healint 的数据平台 Migraine Buddy 提供支持。 这项研究探讨了 AI 如何诊断、调查和查明患者的致命情况，以及它如何在未来几年对全球偏头痛药物市场产生积极影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 片段类型
  • 按给药途径分类的片段
  • 按销售渠道分类的摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 开发具有成本效益的新产品
      • 市场开发
    • 约束因素
      • 严格的监管机构
    • 机会
    • 政府举措
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 监管分析
  • 价格分析
  • 流行病学分析
  • 专利分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌衝突分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第 10 章按类型

  • 预防医学
  • 预防医学

第11章给药途径

  • 口语
  • 注射
  • 其他

第 12 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第13章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第14章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十五章公司简介

  • 雅培实验室
    • 公司简介
    • 产品组合和概述
    • 财务摘要
    • 主要发展状况
  • AbbVie Inc
  • Allergan Plc.
  • AstraZeneca PLC.
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson

第16章 附录

简介目录
Product Code: PH2530

Market Overview

The global migraine drugs market reached USD 4,035.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 9,791.1 million by 2030. The migraine drugs market is expected to exhibit a CAGR of 12.1% during the forecast period (2023-2030), owing to the increase in the preponderance of migraine globally and the increase in awareness regarding migraine and their therapy choices. Additionally, a rise in demand for secure and efficacious therapy and an increase in research and development is anticipated to promote the growth of the market.

Market Dynamics

The Treatment Advancements are Expected to Drive the Migraine Drugs Market Growth During the Forecast Period.

The treatment advancements such as the advancements in new drugs and new drug delivery systems (needle injections, nasal sprays) are expected to drive the global migraine drugs market growth during the forecast period. For example, a few of these medications can treat migraine 2-4 hours into an attack when compared to the pre-existing therapies that perform satisfactorily if administered within 30 minutes.

The Increasing Funding for Clinical Research is Providing Growth Opportunities for Migraine Drugs Market.

The growing funding to the key market players is ensuring growth opportunities for the global migraine drugs market in the upcoming years. For instance, in August 2022, Theranica, an Israel-based digital therapeutics designer concentrated on migraine care, raised around USD 45 million in Series C funding.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

Ukraine and Russia are both extensive bases for international clinical trial activities. The attack on Ukraine may cause an underpowering of global drug development outcomes including drugs for migraine with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including migraine drugs and others.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

In May 2023, Healint, a virtual clinical trial platform-delivering company, partnered with the Saitama Medical University Hospital in Japan to experiment with how AI could be employed to detect migraines. The investigation is fueled by Healint's Migraine Buddy platform for data. The research will investigate how AI could diagnose patients, pick therapies and pinpoint possible fatal circumstances positively impacting the global migraine drugs market in the upcoming years.

Segment Analysis

The global migraine drugs market is segmented based on phase, design, indication, service, and region.

The Retail Pharmacy Segment is Estimated to Hold a 35% Share of the Global Market by 2030.

The majority of migraine preventive or abortive medications are intended for relieving the induced symptoms and averting or subsiding the migraine attack. These medications are primarily analgesics and OTC medicines that are easily available from retail pharmacies. Therefore, the retail pharmacy segment is estimated to hold a dominant share of the global migraine drugs market accounting for around 35.0% of the total market throughout the forecast period.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Migraine Drugs Market During the Forecast Period.

Europe is estimated to hold around 28.2% of the total migraine drugs market owing to the high spending on migraine by European individuals and the efforts by various organizations to spread awareness about migraine in this region. For instance, according to a new article published in September 2022, at the recent Migraine Trust International Symposium, the world's longest-established headache medical conference, supporters gathered jointly to reach for enhanced guidelines for those impacted by migraine. Migraine persists to be a considerable public health issue across Europe costing European economies an assessed €55 billion yearly in immediate and indirect health care costs.

Competitive Landscape

The major global players in the market include: Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson among others.

Why Purchase the Report?

  • To visualize the global migraine drugs market segmentation based on type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of migraine drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Development Of Various New Cost-Effective Products
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Epidemiological Analysis
  • 5.5. Patent Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.1.2. Market Attractiveness Index, By Type
  • 10.2. Abortive Medicine
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Preventive Medicine

11. By Route of Administration

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.1.2. Market Attractiveness Index, By Route of Administration
  • 11.2. Oral *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Injectable
  • 11.4. Others

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospital Based Pharmacies
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Abbott Laboratories
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. AbbVie Inc
  • 15.3. Allergan Plc.
  • 15.4. AstraZeneca PLC.
  • 15.5. Eisai Co., Ltd.
  • 15.6. Endo International Plc.
  • 15.7. GlaxoSmithKline Plc.
  • 15.8. Merck & Co., Inc.
  • 15.9. Pfizer Inc.
  • 15.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us